SIMSA Act of 2025

Bill Number

S. 3228

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Crime and Law Enforcement

Status

Introduced

Latest Action

2025-11-20: Read twice and referred to the Committee on the Judiciary.

Last Updated

2025-12-02T14:58:46Z

AI-Generated Summary

Purpose of the Legislation

The Stop the Importation and Manufacturing of Synthetic Analogues Act of 2025 (SIMSA Act) aims to strengthen controls on synthetic drugs by creating a new category under the Controlled Substances Act (CSA) for analogues—substances chemically similar to illegal drugs—that are imported or offered for import into the U.S. It seeks to prevent abuse by clarifying how these substances are regulated, enabling faster scheduling, imposing penalties, and requiring proper labeling and registration.

Key Provisions

• Establishment of Schedule A: Adds a new sixth schedule (Schedule A) to the CSA for substances that:
• Are imported or offered for import.
• Have a chemical structure and effects (stimulant, depressant, or hallucinogenic) substantially similar to or greater than those in Schedules I-V.
• Are not already scheduled elsewhere.
• "Predicted effects" can be based on chemical structure, scientific data, potential for abuse, or dependence risk.
• Temporary and Permanent Scheduling:
• The Attorney General can temporarily schedule a substance in Schedule A if it meets the criteria and scheduling prevents abuse; orders take effect 30 days after notice and last up to 5 years (extendable by 180 days).
• Permanent scheduling possible after 3 years, unless the Secretary of Health and Human Services determines low abuse potential, triggering immediate termination.
• Temporary orders are not subject to court review; notice must be given to HHS for input.
• Penalties:
• Importing or exporting Schedule A substances carries up to 20 years in prison (up to life if death or serious injury results); fines up to $1 million (individuals) or $5 million (others).
• After a prior felony drug conviction, penalties increase to 30 years (or life if harm results) with higher fines.
• Requires at least 3-6 years of supervised release; no probation if mandatory prison time applies.
• False Labeling Requirements:
• Imported or exported Schedule A substances must be labeled using standard chemical names from the International Union of Pure and Applied Chemistry (IUPAC), unless exempt for FDA-approved drugs or investigational use in clinical trials.
• Violations treated as offenses under the CSA with corresponding fines and penalties.
• Registration Requirements:
• Importers/exporters of Schedule A substances must register if for approved research, analytical, or industrial uses; considers public interest factors like diversion risks and compliance.
• Existing Schedule I/II registrants don't need separate registration.
• Researchers with ongoing studies on newly scheduled substances can continue for up to 30 days while applying; expedited hearings if denial proposed.
• Allows research on Schedule A substances if protocols are verified and consistent with international treaties.
• Conforming Amendments: Updates import/export laws to include Schedule A substances consistently.
• Sentencing Review: If a Schedule A substance is later removed or moved to a lower-penalty schedule, convicted individuals can petition for reduced sentences within 30 days of a court hearing.
• Rules of Construction: Does not limit existing analogue prosecutions or the Attorney General's scheduling authority under prior CSA rules.

Significant Changes to Existing Law

• Introduces Schedule A as a new tool specifically targeting imported synthetic analogues, separate from the existing five schedules (I-V), which focus on broader controlled substances.
• Streamlines scheduling: Temporary orders bypass some prior procedural hurdles (e.g., no judicial review) and HHS input is advisory rather than mandatory for initials.
• Enhances penalties for import/export violations involving analogues, aligning them with high-risk Schedules I/II but adding life sentences for harm-causing cases.
• Mandates IUPAC labeling for analogues, a new requirement not previously specified for unscheduled substances.
• Eases researcher transitions for newly scheduled substances, allowing continued work during applications, which differs from stricter prior CSA rules.

Potential Impacts

• Government Agencies: Empowers the Attorney General (via DEA) and HHS with faster, targeted tools to combat synthetic drug imports, potentially reducing administrative burdens on scheduling but increasing enforcement workload. Customs and border agencies may see more seizures due to clearer criteria.
• Citizens: Increases risks for individuals involved in importing, manufacturing, or using synthetic analogues, with harsher sentences deterring abuse but possibly affecting legitimate researchers or industries. Provides relief for past convictions if substances are later descheduled.
• International Relations: Strengthens U.S. compliance with drug treaties by controlling imports; may lead to more international cooperation on analogue monitoring but could strain trade relations if labeling/registration burdens foreign suppliers.

Main Stakeholders Affected

• Law Enforcement and Regulators: DEA, Attorney General, HHS, and Customs—gain authority but face implementation challenges.
• Importers, Exporters, and Manufacturers: Face new registration, labeling, and penalty rules, especially for synthetic chemical firms.
• Researchers and Medical Professionals: Benefit from streamlined approvals for studies but must navigate quick applications for newly scheduled substances.
• Users and Offenders: Individuals abusing or trafficking synthetic drugs encounter stricter controls and penalties; past convicts may seek sentence reductions.
• Pharmaceutical Industry: Exemptions for FDA-approved products protect legitimate drug development.

Notable Legal, Constitutional, or Political Implications

• Legal: Limits judicial review for temporary scheduling, potentially speeding enforcement but raising concerns about unchecked executive power in drug classification. Preserves prior analogue laws, avoiding conflicts with existing precedents.
• Constitutional: The no-review provision for temporary orders could invite due process challenges (e.g., under the Fifth Amendment) if seen as depriving parties of property or liberty without hearing, though it aligns with similar CSA emergency powers upheld in courts.
• Political: Bipartisan sponsorship (e.g., Grassley, Hassan) reflects consensus on opioid/synthetic drug crises; emphasizes prevention of abuse without broadly expanding schedules, but critics may argue it overregulates emerging chemicals without full scientific vetting.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Grassley, Chuck [R-IA]

Cosponsors (4)

Sen. Hassan, Margaret Wood [D-NH], Sen. Ernst, Joni [R-IA], Sen. Shaheen, Jeanne [D-NH], Sen. Capito, Shelley Moore [R-WV]

Recent Actions

• 2025-11-20: Read twice and referred to the Committee on the Judiciary.
• 2025-11-20: Introduced in Senate

Bill Versions

• Stop the Importation and Manufacturing of Synthetic Analogues Act of 2025 — issued 2025-11-20 — PDF (18 pages)